Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

A Bispecific Antibody Designed to Act as a NRP2/PLXNA1 Agonist Mimics Anticancer Activity of SEMA3F

Thursday, February 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a bispecific antibody developed by aTyr that acts as a NRP2/PLXNA1 agonist, mimicking the anticancer activity of SEMA3F. This innovation could lead to new therapeutic avenues in cancer treatment. The potential efficacy of this approach is highlighted, showcasing its relevance in the ongoing battle against cancer.
Price reaction · baseline $0.9942 (2026-02-18 close) · hit pre-market · 1 other ATYR headline(s) in the window, move may be shared
day 0 close · peak
+5.6%
day 1
+4.6%
day 3
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • The bispecific antibody shows potential anticancer activity.
  • It mimics the effects of SEMA3F, which is promising for cancer treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is the function of the bispecific antibody?

The bispecific antibody acts as a NRP2/PLXNA1 agonist, mimicking SEMA3F's anticancer activity.

Who developed the bispecific antibody?

The bispecific antibody was developed by aTyr Pharma.

What potential does this antibody have?

It shows potential for new therapeutic approaches in cancer treatment.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare cancer treatment SEMA3F NRP2 PLXNA1
Last updated: Feb 19, 2026

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →